Quick Takeaways
- EVENTIDE ASSET MANAGEMENT, LLC filed SCHEDULE 13G/A for Nektar Therapeutics Common Stock, $0.0001 par value (NKTR).
- Disclosed ownership: 3.6%.
- Date of event: 31 Dec 2024.
EVENTIDE ASSET MANAGEMENT, LLC - 31 Dec 2024 SCHEDULE 13G/A Report for Nektar Therapeutics Common Stock, $0.0001 par value (NKTR)
- Filing Manager
- EVENTIDE ASSET MANAGEMENT, LLC
- Reporting Manager
- Eventide Asset Management, LLC
- Symbol
- NKTR
- Shares outstanding
- 184,210,526 shares
- Disclosed Ownership
- 6,650,000 shares
- Ownership
- 3.6%
- Form type
- SCHEDULE 13G/A
- Filing time
- 14 Feb 2025, 12:08:11 UTC
- Date of event
- 31 Dec 2024
- SEC
- View on sec.gov
Quoteable Key Fact
"EVENTIDE ASSET MANAGEMENT, LLC disclosed 3.6% ownership in Nektar Therapeutics Common Stock, $0.0001 par value (NKTR) on 31 Dec 2024."
What Changed
- No earlier schedule filing is available for direct comparison.
- Current filing was accepted on 14 Feb 2025, 12:08.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Source Evidence
Backed by Schedule 13D/13G
See Original Filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting Managers (3)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Eventide Asset Management, LLC | 3.6% | 6,650,000 | 6,650,000 | 0 | /s/ Peter J. Luiso | Peter J. Luiso, General Counsel | |
| Finny Kuruvilla, M.D., Ph. D. | 3.6% | 6,650,000 | 0 | 6,650,000 | /s/ Finny Kuruvilla, M.D., Ph. D. | Finny Kuruvilla, M.D., Ph. D. | |
| Robin C. John | 3.6% | 6,650,000 | 0 | 6,650,000 | /s/ Robin C. John | Robin C. John |